Floatz logo

TTI 101

Gastric Adenocarcinoma

Tvardi Therapeutics, IncorporatedSmall moleculePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

65 Active assets in the Gastric Adenocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Boehringer Ingelheim
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Mayo Clinic
Phase 3BB
Capecitabine
Shanghai Zhongshan Hospital
Phase 3BB
Eloxatin
Shanghai Zhongshan Hospital
Phase 3BB
TRASTUZUMAB
Boehringer Ingelheim
Phase 2BB

View all 50 →

Same molecule, other indications

TTI 101 is also rated in:

hepatocellular carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
idiopathic pulmonary fibrosisDormant
CCC
Indicative ·
54 / 100
View asset →
cancerDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →